Connect
MJA

Second primary cancers in people who had cancer as children: an Australian Childhood Cancer Registry population‐based study

Danny R Youlden, Peter D Baade, Adèle C Green, Patricia C Valery, Andrew S Moore and Joanne F Aitken
Med J Aust 2020; 212 (3): . || doi: 10.5694/mja2.50425
Published online: 20 January 2020

Abstract

Objective: To investigate the incidence of second primary cancers in people diagnosed with cancer during childhood.

Design, setting: Retrospective, population‐based study; analysis of Australian Childhood Cancer Registry data.

Participants: People alive at least two months after being diagnosed before the age of 15 years with a primary cancer, 1983–2013, followed until 31 December 2015 (2–33 years' follow‐up).

Main outcome measures: Risks of second primary cancer compared with the general population, expressed as standardised incidence ratios (SIRs).

Results: Among 18 230 people diagnosed with cancer during childhood, 388 (2%) were later diagnosed with second primary cancers; the estimated 30‐year cumulative incidence of second cancers was 4.4% (95% CI, 3.8–5.0%). The risk of a new primary cancer was five times as high as for the general population (SIR, 5.13; 95% CI, 4.65–5.67). Relative risk of a second primary cancer was greatest for people who had childhood rhabdomyosarcoma (SIR, 19.9; 95% CI, 14.4–27.6). Relative risk was particularly high for children who had undergone both chemotherapy and radiotherapy (SIR, 9.80; 95% CI, 8.35–11.5). Relative risk peaked during the 5 years following the first diagnosis (2 to less than 5 years: SIR, 10.3; 95% CI, 8.20–13.0), but was still significant at 20–33 years (SIR, 2.58; 95% CI, 2.02–3.30). The most frequent second primary cancers were thyroid carcinomas (65 of 388, 17%) and acute myeloid leukaemias (57, 15%).

Conclusions: Survivors of childhood cancer remain at increased risk of a second primary cancer well into adulthood. As the late effects of cancer treatment probably contribute to this risk, treatments need to be refined and their toxicity reduced, without reducing their benefit for survival.

  • Danny R Youlden1,2
  • Peter D Baade1,2,3
  • Adèle C Green4,5
  • Patricia C Valery4
  • Andrew S Moore6,7,8
  • Joanne F Aitken1,2,9,10

  • 1 Cancer Council Queensland, Brisbane, QLD
  • 2 Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD
  • 3 Queensland University of Technology, Brisbane, QLD
  • 4 QIMR Berghofer Medical Research Institute, Brisbane, QLD
  • 5 Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom
  • 6 University of Queensland Diamantina Institute, Brisbane, QLD
  • 7 Queensland Children's Hospital, Brisbane, QLD
  • 8 Child Health Research Centre, University of Queensland, Brisbane, QLD
  • 9 Institute for Resilient Regions, University of Southern Queensland, Brisbane, QLD
  • 10 University of Queensland, Brisbane, QLD


Acknowledgements: 

Patricia Valery was supported by an NHMRC Career Development Fellowship (1083090). We thank Leisa O'Neill and Chloe Henshaw for their work in the Australian Childhood Cancer Registry. We also acknowledge the assistance of all Australian state and territory cancer registries, the Australian Institute of Health and Welfare, and each of the major paediatric oncology treating hospitals throughout Australia.

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.